Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S066 - Wounds and Ulcers: The Good, the Bad and the Ugly

Monday, February 19; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Formulate an expanded differential diagnosis for wounds seen in clinical practice
  • Recognize skin signs of systemic disease as it relates to wounds and wound care
  • Utilize technology, pharmacology, and appropriate devices to improve the diagnosis, treatment, and prevention of acute and chronic wounds


Wound Care is dermatology at its finest. As we discuss the scope of wound care issues in the US and worldwide, and the critical role of dermatologists in this field, we will follow with excellent presentations covering clinical and practical pearls for the diagnosis, treatment, and prevention of acute and chronic wounds. We will make this session lively and interactive with a panel discussion on the improvement of quality performance halfway through and attempt to make the final session on the prevention of venous leg ulcers hands-on as possible.


  • Fivenson, David P., MD: Abbott Laboratories – I(Grants/Research Funding), SP(H); AbbVie – SP(Fees); Actelion – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); BestDoctors – Independent Contractor(Fees); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); DermTech International – SH(NC); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); Eli Lilly and Company – SP(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(Fees); Glenmark Generics Inc. – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); L.E.K. Consulting – C(Fees); LEO Pharma, US – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – I(Grants/Research Funding); Novum – I(Grants/Research Funding); Pfizer Inc. – SP(H); Promius Pharma, LLC – I(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Symbio – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); XOMA (US) LLC – I(Grants/Research Funding);
  • Lev-Tov, Hadar, MD: BSN Medical – I(Grants/Research Funding); DermVeda – F(SO); Factor Therapeutics – I(NC); Molynlycke – I(NC); SAWC – SP(H); TissueTech – I(NC);
  • Maderal, Andrea, MD: no financial relationships exist with commercial interests.
  • Mostow, Eliot N., MD: Cook Biotech Inc. – C(Fees); Elsevier Inc. – C(S); Vivacare – A(OB);
  • Tang, Jennifer C, MD: no financial relationships exist with commercial interests.
Monday, February 19
1:00 PM
Dr. Mostow / Wound Care: A Call to action for Dermatologists to be Involved
1:20 PM
Dr. Fivenson / The A to Z of Wounds: 'WHAT'S UNDER THE ULCER?'
2:00 PM
Dr. Maderal / Connective Tissue Disease and Wounds
2:40 PM
All faculty / Getting it Right: Improving Diagnostic Accuracy In Wound Care
2:50 PM
Dr. Tang / Acute wound healing pearls
3:20 PM
Dr. Lev-Tov / Preventing Venous Leg Ulcers
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 24C
  • CME Credits
  • Type
  • Andrea Maderal, MD, FAAD
  • David P. Fivenson, MD, FAAD
  • Hadar Lev-Tov, MD, FAAD
  • Jennifer C Tang, MD, FAAD